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Immunological self-tolerance is maintained in two stages; central
and peripheral tolerance. The thymus orchestrates self-tolerance
by negative selection (clonal deletion) of self-reactive T cells and
by producing CD4+CD25highFoxp3+ regulatory T cells (Tregs).
Tregs are essential for the maintenance of peripheral self-toler-
ance and immune homeostasis in various tissues including the
liver [1]. Depletion of Tregs in rodents result in spontaneous
development of a variety of organ-speciﬁc and systemic autoim-
mune diseases and reconstitution of Tregs prevents disease
development [2]. Tregs constitutively express the transcription
factor FOXP3. In humans, mutations in the FOXP3 gene result in
impairment of Treg development and function. This leads to the
occurrence of immune-dysregulation, polyendocrinopathy,
enteropathy, X-linked (IPEX) syndrome accompanying autoim-
mune diseases (in particular, type 1 diabetes and thyroiditis),
inﬂammatory bowel disease, and allergy [1]. In addition to their
thymic origin, FOXP3+ Tregs can also be generated in the periph-
ery (Addendum). FOXP3 is essential for the development of Tregs,
yet its expression is insufﬁcient for establishing the Treg cell line-
age. Treg cell development was achieved by the combination of
two independent processes, i.e., the expression of FOXP3 and
the establishment of a Treg cell-speciﬁc CpG hypomethylation
pattern [3]. They both are required for Treg cell-type gene expres-
sion, lineage stability, and full suppressive activity. Thymus-
derived and/or peripherally generated FOXP3+ Tregs control a
variety of lymphocyte populations, especially CD4+ helper T
(Th) cells and CD8+ cytotoxic T cells.
The liver is constantly exposed to food antigens and low levels
of endotoxin from the gut via the portal vein. Thus it requires
mechanisms to suppress immune responses to harmless antigens
whilst maintaining the capacity to respond to infectious agents
[4]. Blood enters the liver parenchyma via the hepatic sinusoids,
which is a low-ﬂow fenestrated vascular channels lined by liverJournal of Hepatology 20
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Open access under CC BY-sinusoidal endothelial cells (LSEC) [4]. Recruitment of various
lymphocyte subsets including Tregs occurs mainly within hepatic
sinusoids [5], which are interspersed with the liver resident mac-
rophages, Kupffer cells. The space of Disse lies beneath the endo-
thelium and contains vitamin A enriched hepatic stellate or Ito
cells (Fig. 1).
Hepatic inﬂammation of any aetiology is characterized by
lymphocyte inﬁltration. Both effector lymphocytes (Th1, Th17,
cytotoxic CD8 cells) and regulatory T cells are present in the
human liver. The normal liver contains a low frequency of CD8,
CD4 effector, and regulatory T cells, however, inﬂammatory and
autoimmune liver diseases are associated with enrichment of
both subsets of lymphocytes [6,7]. The balance of effector and
regulatory cells generally determines the outcome of hepatitis.
If the initial insult, which causes acute hepatitis, is removed
(e.g., hepatitis A viral infection or drug induced hepatitis), it is fol-
lowed by regeneration of hepatocytes and biliary epithelial cells
and this may lead to full recovery. Sometimes, acute hepatitis
leads to fulminant hepatitis. The protective effect of Tregs in ful-
minant hepatitis had previously been reported in mouse models
[8]. If the noxa persists (e.g., HBV, HCV, and autoimmune hepati-
tis) and the acute hepatitis, which is caused by effector T cells, is
not controlled by the regulatory arm of the immune system, this
could lead to chronic lobular or interface hepatitis [9], resulting
in complications such as cirrhosis, liver failure, and hepatocellu-
lar carcinoma (Fig. 1). Thus, the control of hepatic inﬂammation is
a crucial initial step to prevent subsequent complications. Tregs,
which attenuates inﬂammation by suppressing effector T cells
proliferation and cytokine secretion, play this pivotal role of con-
trolling hepatitis.
Autoimmune hepatitis (AIH) is characterized by a loss of
immunological tolerance to hepatocytes. An effector CD4 and
CD8 T-cell immune response to auto-antigen is the underlying
pathogenic mechanism of AIH. Preventing recurrent attacks of
hepatitis in AIH is the mainstay for prevention of liver cirrhosis
and liver failure [10]. The international Autoimmune Hepatitis
Group classiﬁed AIH into two main types. Although cytochrome
P450IID6 (CYP2D6) is the target auto-antigen for type-2 AIH
(Fig. 1), the identity of the auto-antigen is still unknown in
type-1 AIH. The advantage of a known antigen is the possibility
of generating auto-antigen speciﬁc Tregs therapy in type-2 AIH.
Long-term immunosuppression is the standard treatment to
achieve remission, but progression to end-stage liver disease
occurs in 10–20% of patients, requiring liver transplantation.
Given their essential role in controlling autoimmunity,13 vol. 59 j 1127–1134
NC-ND license.
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autologous Treg replacement in AIH is an attractive and promis-
ing therapeutic option to restore hepatic immune self-tolerance.
Tregs have well-established roles in suppressing anti-tumor
immunity, with Tregs depletion in mouse models of cancer
improving tumor rejection [11]. Numbers of Tregs are increased
in the blood and peri-tumor region of patients with many differ-
ent cancers including hepatocellular carcinoma [12]. Tregs inhibit
tumor-speciﬁc CD8+ and CD4+ T-cell effector functions and they
are one mechanism of tumor-driven immune evasion. Similarly,
the pathogenesis and outcome of viral hepatitis are signiﬁcantly
inﬂuenced by the host immune response. Failure of the T-lym-
phocyte-mediated immune response is the main culprit in the
chronicity of viral liver diseases. Viral persistence is associated
with Treg-driven impaired expansion, cytokine secretion, and
effector functions of virus-speciﬁc CD8+ T cells [13,14]. Manipula-
tion of Tregs also controls HCV induced autoimmune-related con-
ditions; for example, administration of low-dose interleukin-2
led to Treg recovery and concomitant clinical improvement in
patients with HCV-induced vasculitis [15].
Transplantation of solid organs such as the liver requires
intensive immunosuppression to prevent graft rejection. Liver
transplant (LT) recipients are typically on life-long immunosup-
pressive therapy, which non-speciﬁcally dampens down their
entire immune system, exposing them to increased long-term
risks of cancer and infection. Of note, following LT, there is a selec-
tive group of patients who self-discontinue immunosuppressive
therapy or are deliberately withdrawn due to side effects and
who maintain normal graft function. This operational tolerance
(no immunosuppression and normal allograft function) patient
group may have a different Treg proﬁle to patients who need con-
tinued immunosuppression. In general that AIH LT recipients have
recurrence of autoimmune inﬂammation in the graft, requiring
lifelong low dose steroid therapy. Treg therapy could potentially
beneﬁt these patients and those who had liver transplantation
for other indications, permitting them a steroid-free and immuno-
suppression-free period following transplantation.
Whilst the evidence cited above makes a clear case for the
importance of Tregs in hepatic immune homeostasis, it is impor-
tant to note that control of hepatic inﬂammation is complex and
maintained not only by Tregs, but also by other immune cells.
Hence NK cells protect against autoimmune- mediated tissue
damage by acting on dendritic cells and deletion of activated T
cells [16,17]. Similarly, regulatory B cells [18] and CCR9 express-
ing plasmacytoid dendritic cells also maintain immune tolerance
[19]. However, for the remainder of this review, we focus on the
immunomodulatory roles of Tregs speciﬁcally and illustrate their
important potential as a therapeutic tool.Fig. 1. Regulatory T cells (Tregs) recruitment, its role in autoimmune hepatitis, viral h
from the gastrointestinal tract via portal vein and hepatic artery from the systemic cir
inﬂamed human liver via hepatic sinusoids using chemokine receptor CXCR3. FOXP3+
(CTLA-4 and dendritic cells) and immunosuppressive cytokines IL-10 and TGF-b. Tregs
essential in re-establishing hepatic tolerance in autoimmune liver disease, such as au
lymphocytes in HCV/HBV infection. They are involved in the immune escape mechanism
clearance. Plasma cells are involved in autoimmune hepatitis by secreting autoantibodi
Journal of Hepatology 2013Tregs cellular therapy to restore immune self-tolerance in
autoimmune hepatitis
Evidence suggests that a quantitative and/or functional deﬁ-
ciency in Tregs plays a key role in the pathogenesis of autoim-
mune hepatitis and other autoimmune diseases [5] [20–23].
Thus switching the balance towards regulatory dominance by
using cellular therapy to enrich hepatic functional Tregs is a rea-
sonable treatment strategy for restoring self-tolerance. This could
potentially be achieved by leukopharesis and infusion of selective
liver homing antigen-speciﬁc Tregs into AIH patients. In type 2
AIH, currently there are protocols in development to manufacture
autologous CYP2D6 antigen-speciﬁc Tregs, however, polyclonal
Tregs are the only option so far for type 1 AIH [24]. It is important
to note that not only in autoimmune hepatitis but also other
autoimmune diseases, such as Type 1 diabetes and systemic
lupus erythematosus, some T effector cells are not susceptible
to suppression by Tregs [25–27].
Tregs in peripheral blood express the chemokine receptor
CXCR3 and this is highly enriched in the inﬂamed liver [5].
CXCR3 ligands are expressed on the inﬂamed human hepatic
sinusoidal endothelium [28]. Thus, this chemokine/chemokine
receptor could be potentially targeted to inhibit Treg recruit-
ment within the intrahepatic microenvironment. However, tar-
geting of CXCR3, which is also highly expressed on effectors
and Th17 cells, poses a challenge for selective manipulation
of Treg recruitment [28,29]. Alternately, targeting of speciﬁc
cytokine could also potentially modulate Treg phenotype and
function. This is exempliﬁed by the use of IL-2, which is crucial
for the maintenance of FOXP3 Tregs. Administration of IL-2/
anti-IL-2 mAb complexes can dominantly expand Tregs
[30,31]. Thus, augmenting selective recruitment of Tregs in
the liver, or selectively expanding Tregs by IL-2 or IL-2/anti-
IL-2 complex administration could be potentially applied to
suppress ongoing hepatitis (Table 1).
As AIH is a relapsing, remitting disease, the timing of admin-
istration (acute, remission or relapse) of autologous Tregs to
patients would be a critical factor in restoring hepatic self-toler-
ance. It would be reasonable to conduct an initial study of Good
Manufacturing Practice (GMP) grade autologous Treg homing to
the liver in non-cirrhotic AIH patients who have relapse of hepa-
titis. Depending on the initial result, this could then be followed
by extending the study to AIH cirrhotic patients. The therapeutic
application of Tregs should be applied to the difﬁcult-to-treat
patient group who does not respond to immunosuppression,
and antigen-speciﬁc expanded autologous Tregs would be the
best option of these patients.epatitis, and hepatocellular carcinoma. The human liver has a dual blood supply
culation. Regulatory T cells (CD4+CD25highCD127lowFOXP3+) are recruited to the
Tregs exert their function by multiple mechanisms including contact dependent
control hepatitis (both lobular and interface) caused by Th1, CD8 cells. Tregs are
toimmune hepatitis, and prevent excessive hepatocyte destruction by effector
of hepatocellular carcinoma by inhibiting cytotoxic T cells (CD8 and Th1) tumour
es. LSEC, liver sinusoidal endothelial cells.
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Table 1. Potential options for Tregs cellular and Treg-directed therapies in human liver diseases.
A Enrichment of Treg frequency and function (autoimmune liver diseases and post-liver transplant)
I. Genetic manipulation
• TCR gene transfer into Tregs; generation of large quantity of  Tregs by T cell receptor gene transfer with clini-
cal grade lentiviral vector [58]
• Transfection of non-Tregs cells with FOXP3 to generate Tregs
II. Autologous Tregs administration as adoptive cellular therapy
III. Cytokines and vitamins supplementation
• IL-2/anti-IL-2 complex for autoimmune liver diseases and post-liver transplant [31]
• Low dose IL-2 supplement [15]
• All Trans-Retinoic Acid (ATRA), vitamin D  [54, 59]
B Inhibition or attenuation of Treg function locally (applicable to hepatocellular carcinoma)
I. Targeting functional molecules
• Daclizumab; Basiliximab (anti-CD25)
• Denileukin diftitox (local depletion of Tregs) [37]
• CTLA-4 blockade [39]
C
I. Neutralizing or blocking  cytokines [47, 49]
• (Anti-IL-6, anti-IL-12)
II. Enrichment of vitamins to maintain regulatory phenotype [54, 60]
• Vitamin D, ATRA
III. Supplementing exogenous drugs to maintain stability of Tregs [59, 60]
• Rapamycin
D Inhibiting Treg recruitment via chemokine receptors to dampen their activity (applicable to hepatocellular carcinoma)
I. Anti-CCR6; anti-CCR4 to attenuate Treg frequency [33, 34]
antigen-specific
Maintaining phenotype and function of Treg in the inflamed intrahepatic microenvironment
inflammatory
Clinical Application of Basic ScienceEnrichment of Tregs to augment suppression of effector T cells
in acute fulminant hepatitis
Tregs could potentially help protect patients from fulminant hep-
atitis, which leads to massive hepatic necrosis. Tregs protect the
immune-mediated liver damage by suppressing effector T cells in
mouse acute hepatitis B infection [32]. Again, in a mouse model
of T cell-mediated fulminant hepatitis, depleting Tregs aggra-
vated liver injury, whereas adoptively transferring them reduced
liver injury [8]. However, application of Tregs as therapy in this
context warrants careful consideration. Certainly, Treg-directed
therapy might be an option in fulminant hepatitis to control
aggressive T-effector cell response to hepatocytes along with
standard therapy while waiting on transplant list. However,
potential application of Tregs in fulminant hepatitis (such as ful-
minant hepatitis B and fulminant seronegative hepatitis) patients
requires more detailed knowledge of virus speciﬁc T-effector cell
and Treg immune-biology, the role of Tregs in fulminant liver
failure and involvement of other immune cells to prevent the dis-
turbance of immune homeostasis and self-tolerance. Since man-
ufacturing of sufﬁcient numbers of Tregs would require some
time, direct inhibition of pro-inﬂammatory cytokines along with
targeting of endogenous Treg-associated molecules may present
a better solution. Regardless of the strategy, it is essential that
these patients are on urgent liver transplant waiting lists and
studies should only be carried out in centers where liver trans-
plantation is available to assure the safety of patients.1130 Journal of Hepatology 2013Promoting anti-tumour immunity in hepatocellular
carcinoma by attenuating Tregs
Immunotherapy represents an attractive therapeutic option for
patients with hepatocellular carcinoma (HCC). FOXP3+ Tregs are
one of the mechanisms of tumor-driven immune evasion as they
inhibit tumor-speciﬁc CD8+ and CD4+ T-effector cells functions.
An increase in Tregs frequency was indeed noted in both periph-
eral blood and tumor margin of HCC patients, which correlates
with poor survival [12]. This is the main obstacle tempering suc-
cessful tumor immunotherapy. Thus, a strategy to deplete local
Tregs, while preserving host immune response, would augments
HCC immunotherapy.
Recruitment of Tregs and T-effector cells to HCC depends on
the selective expression of chemokines in the tumor tissue and
chemokine receptor expression on the lymphocytes. Tregs are
selectively recruited to tumor tissues via CCR6 on circulating
Tregs and CCL20 secreted by tumor cells or tumor-inﬁltrating
macrophages [33], or via Treg expressing CCR4 [5] and CCL22
from tumor tissues [34]. Thus blocking these pathways would
be a viable option to decrease the frequency of Tregs in tumor tis-
sue and prevent immune escape in HCC (Table 1).
The CD25-blocking monoclonal antibody, daclizumab (a
humanized anti-IL-2 receptor antibody), reduces FOXP3+
CD25high CD45RAneg Treg numbers, attenuates their suppressive
function, and reprograms Tregs to IFN-c-secreting T cells [35].
Denileukin diftitox (a fusion protein of IL-2 and diptheria toxin)vol. 59 j 1127–1134
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has been reported to deplete Tregs in solid organ tumor and could
be a potential therapy [36,37]. Cytotoxic T lymphocyte-associ-
ated antigen 4 (CTLA-4) blockade and depletion of CD25+ Tregs
in anti-tumour therapy have been shown to be effective
[38,39]. Thus local therapy applying these approaches may lead
to a decline in Treg frequency and robust priming and boosting
of anti-HCC CD8 and CD4 T-cell responses (Table 1). Thus, poten-
tial approaches for HCC patients would be to administer these
blocking antibodies or antibody in combination with anti-HCC
vaccine for tumour-associated antigens such as alpha-fetoprotein
(AFP) and glypican-3.Maintaining the post-transplantation tolerance
Immunotherapy by the adoptive transfer of Tregs in post liver
transplant patients may have several advantages over conven-
tional immunosuppressive therapy. Lifelong immunosuppression
prevents liver allograft rejection; however, its side effects such as
renal failure, metabolic complications, and long-term risk of
malignancy are disadvantages. Such complications could be min-
imized by using strategies to boost the number of Tregs within
the graft with a view to reducing reliance on pharmacological
immunosuppression. Induction strategies such as anti-thymocyte
globulin (ATG) induce lymphopenia with a preferential preserva-
tion of Tregs [40]. Current immunosuppressive drugs such as
rapamycin promote selective Treg expansion [41] and it would
be beneﬁcial for enhancing Treg frequency in transplant recipi-
ents. Alloantigen-speciﬁc human Tregs had been reported as a
potent suppressor of graft damage in a humanized mouse model
[42]. Thus, tailoring the immunosuppressive regimen to boost
Treg frequency, along with administration of ex vivo expanded
alloantigen-speciﬁc Tregs that were harvested before liver
transplantation, may potentially be a future ‘‘customized Tregs
therapy’’ to maintain post-transplant tolerance.
Tregs therapy could also beneﬁt post-liver transplant patients
to prevent acute rejection. Liver transplant patients with acute
rejection have been shown to have a low level of circulating Tregs
[43]. Furthermore, Tregs could also be used for monitoring of post
liver-transplant recipients. Assessment of intra-graft FOXP3
mRNA expression in liver transplant-recipients could detect
HCV graft recurrence and a previous episode of acute rejection
[44]. Thus, FOXP3 gene expression proﬁling in the graft together
with clinical, immunological and viral parameters may be useful
for immune monitoring and subsequent management in post-
transplant patients.Treg cellular therapy in liver diseases and challenges ahead
Adoptive transfer of ex vivo expanded CXCR3+ Tregs in mice with
T-cell mediated injury has been shown to efﬁciently target the
inﬂamed liver, restores peripheral tolerance, and induce remis-
sion [45]. Therefore, cellular immunotherapy exploiting puriﬁed
and expanded FOXP3+ Tregs to treat T-cell-mediated liver dis-
eases is a future goal for both hepatologists and immunologists.
Currently, several groups are developing protocols for generating
GMP grade Tregs to use in autoimmune diseases and solid-organ
transplantation. However, except in the setting of GVHD, there is
no preclinical study of Tregs therapy in the solid organs such as
the liver.Journal of Hepatology 2013Several questions still remain to be addressed before thera-
peutic application of GMP grade Tregs becomes a reality for liver
patients. Optimization of the number, route, and frequency of
Tregs to administer is essential to obtain the desired effect and
prevent unwanted side effects. Correct timing of Treg therapy
and selection of a speciﬁc patient cohort (e.g., AIH patients in
relapse) are also crucial for successful therapy. Recently
described CD45RA+FOXP3low resting Tregs (rTregs) generally
maintain their suppressive function and stability after expansion
[46] thus this population may be the ideal population for clinical
applications. In type 2 AIH, antigen-speciﬁc Tregs could be gener-
ated following co-culture with semi-mature dendritic cells
loaded with CYP2D6 peptides [24]. However, in type 1 AIH, poly-
clonal Tregs would need to be used for cell therapy at present due
to the current lack of identiﬁable target antigens.
Maintenance of the phenotypic stability and suppressive
capacity of infused Tregs in the inﬂamed intra-hepatic microenvi-
ronment is also a key prerequisite for utilising these cells for
therapy. The inﬂamed intrahepatic microenvironment is enriched
with pro-inﬂammatory cytokines such as IL-6 and IL-12. These
cytokines may play a crucial role in Treg plasticity, frequency
and FOXP3 and IL2R expression [47–49]. Neutralization of these
cytokines may stabilize the Treg phenotype (Table 1). FOXP3
Tregs could functionally differentiate to Th1 or Th17 lineages in
the inﬂamed microenvironment by upregulation of T-bet, RORc,
and expression of IFN-c and IL-17 [47,50]. Current available evi-
dence suggests that rapamycin, an mTOR inhibitor, selectively
expands the Treg population, protects against plasticity to other
lineages, and maintains regulatory phenotype and suppressive
capacity [41]. All-Trans Retinoic Acid (ATRA) has also been
reported to sustain the stability and function of Tregs in an
inﬂammatory milieu [51] and IL-2 is crucial for Treg survival
and proliferation [52]. Thus, GMP grade rapamycin, IL-2, and
ATRA could be necessary ingredients for in vitro expansion of
Tregs to maintain stable Treg phenotype and function (Table 1).
GMP medium (i.e., TexMACS) could be potentially used as basic
medium for isolated Tregs and these reagents could be incorpo-
rated into future GMP grade Tregs medium formulation during
the expansion process (Table 1). It is essential to start the expan-
sion culture with highly puriﬁed CD4+ CD25high CD127low Tregs
cells and then to create a culture condition with the above
reagents that favor Treg outgrowth. Genetic manipulation and
supplementation with vitamin D are also emerging areas of
intense research for Treg immune regulation [53,54] (Table 1).
Although the medium formulations are optimized for maintain-
ing stable phenotype and function, Treg stability should be tested
by analysing the epigenetic status of the Treg Speciﬁc Demethy-
lated Region (TSDR) of the FOXP3 gene in isolated cultured Treg
[55].
An initial challenging step in hepatic Treg therapy would be to
ascertain that adoptively transferred Tregs are indeed recruited
to the liver. Both human and murine Tregs highly express the
liver homing chemokine receptor CXCR3; and inﬂamed hepatic
sinusoids express high levels of CXCR3 ligands [5,28,56]. An ini-
tial, pilot preclinical cell tracking study to observe the homing
dynamics of Tregs would be necessary to conﬁrm that they accu-
mulate at the site of hepatic inﬂammation, followed by a dose
escalation study to monitor the safety and efﬁcacy. Regular Treg
infusion therapy with autologous ex vivo expanded, antigen-
speciﬁc CXCR3+ Tregs in AIH patients with monitoring of immu-
nological, biochemical, histological, and clinical parameters
could be a realistic therapeutic approach to re-establish hepaticvol. 59 j 1127–1134 1131
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self-tolerance, induce remission of AIH, and maintain post-liver
transplant tolerance without immunosuppression in the near
future (Table 1).
In addition, safe use of customised Tregs in clinics requires
manufacture of Tregs with GMP grade reagents and equipment
(e.g., Prodigy) in a sterile, fully automated closed system. Current
Treg isolation protocols are limited, because the available clinical
GMP grade Tregs reagents only utilize CD4 and CD25 as surface
markers. GMP grade cell-sorting, with application of other impor-
tant surface markers such as anti-CD127 and anti-CD45RA, could
soon be an available option to obtain a pure Treg population. The
ﬁnal hurdle and challenge to successful application would be to
fulﬁl strict legislation from regulatory authorities such as the
Medicines and Healthcare products Regulatory Agency (MHRA)
in the UK and FDA in the US. Such agencies oversee the quality
control, clean-room facilities, sterility, purity, GMP grade equip-
ment and reagents, contracts and documentation for transla-
tional trials of investigational medicinal products (IMP) such as
GMP Treg production and adoptive cellular therapy.
Key Points
• Tregs play multiple roles in the immunopathology of
liver diseases 
• Tregs are crucial in maintaining hepatic immunological
self-tolerance. Enrichment of autologous Tregs would 
be beneficial in autoimmune liver diseases and post
liver transplantation. Attenuating Tregs frequency 
and function is a potential therapeutic option in 
hepatocellular carcinoma
• Maintaining stable phenotype and suppressive function
in the inflamed intrahepatic microenvironment is vital
for successful therapeutic application in liver diseases
• Correct timing and frequency of administration, 
provision of adequate cells numbers, choice of Tregs
and their antigen-specificity are mainstays of achieving
adoptive cell therapyConclusion
Immuno-regulation in liver disease is complex. It is possible that
a combination of Treg supplementation/depletion with other
modalities of immune manipulation (GMP grade cytokines or
anti-cytokines) and gene therapy may be required to achieve
effective immune regulation and to prevent undesired risks.
There is a great potential for the use of autologous Tregs in
patients with AIH and post-liver transplantation. Treg adminis-
tration would be beneﬁcial for restoring tolerance thus correctly
timed, GMP grade Treg infusion is a promising future cellular
therapy approach for these clinical settings. The era of ‘‘lifelong
immunosuppression’’ could be potentially replaced by a new
era of ‘‘personalized Treg therapy’’, thereby avoiding the unde-
sired side effects of immunosuppression. On the other hand,
damping down the Treg activity by targeted depletion of
Treg-related molecules in acute viral or fulminant hepatitis and
HCC could be a potential approach to prevent inhibition of
beneﬁcial effector T-cell responses by Tregs. It is essential to1132 Journal of Hepatology 2013make sure that Tregs do not revert back to conventional T cells
or other T cell lineages and maintain their function during any
expansion process by meticulous monitoring. Investigators
should also be aware that excessive Treg activity could inhibit
the host response to infectious agents. Genomic and immune-
phenotype analysis of Tregs should be incorporated into the
individualized personal proﬁle of potential patients. Selecting
individual patients by their immune characteristics and speciﬁc
disease states, with correct timing, should increase the chance
of successful therapy. Hopefully, depending on the outcome of
preclinical studies, Treg cellular therapy and Treg-directed thera-
pies may arrive to the liver clinics as next generation treatments
in the near future.Addendum
A recent conference on Tregs and Th subsets recommended
simple nomenclature for the basic and clinical immunologist
community [57]. According to the recommendation, ‘‘Thymus-
derived Treg (tTreg) cells’’ should be used instead of ‘‘natural Treg
(nTreg) cells’’. ‘‘Peripherally-derived Treg (pTreg) cells’’ should be
used instead of ‘‘induced or adaptive Treg (iTreg/aTreg) cells’’.
‘‘In vitro-induced Treg (iTreg) cells’’ should be used to distinguish
between those Treg populations generated in vivo vs. in vitro.Financial support
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